Vir Biotechnology has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for ...

A recovering IPO market, surging mergers and acquisitions fuel more biotech venture deals.

Biotechnology companies are coming out of a dark period for the industry. Why has the tide turned and is now a good time to ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

I had the opportunity to participate in a panel discussion reflecting on my experiences working with both EBRC and the ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

By Milliam MurigiKenya’s animal feed manufacturers are urging the government to allow access to genetically modified (GM) ...